Anthera raising $40m for blisibimod Phase III trials in lupus after Phase II miss
This article was originally published in Scrip
Executive Summary
Anthera Pharmaceuticals will sell 60.6 million shares of common stock at $0.66 per share for proceeds of $40 million to fund two Phase III clinical trials and a Phase II orphan disease study for its sole drug candidate blisibimod, which missed the primary endpoint in a Phase IIb lupus trial last year.